Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.

Journal of clinical pathology - 1 Aug 2016

Turakhia Samir K, Murugesan Gurunathan, Cotta Claudiu V, Theil Karl S

Abstract excerpt

AIMS: Marked thrombocytosis is uncommon in chronic myelogenous leukaemia (CML) but may be associated with mutation of JAK2 V617F, calreticulin (CALR) and/or phospho-STAT5 (p-STAT5) activation in other myeloproliferative neoplasms (MPNs), particularly essential thrombocythaemia (ET). We investigated the JAK2 V617F, CALR and STAT5 activation status in patients with CML and thrombocytosis (CML-T) that mimicked ET,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to STAT5 Transcription Factor

Share to Thrombocythemia, Essential

Share to Thrombocytosis

Source

Identifiers

PMID: 26754830
DOI: 10.1136/jclinpath-2015-203498

Genes

JAK2
CALR
ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.PMID 26754830Read ↗

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Semantic proximity Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.Semantic proximity Read ↗

Calreticulin mutations in essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].Semantic proximity Read ↗

Somatic mutations of calreticulin in myeloproliferative neoplasms.Semantic proximity Read ↗

Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.Semantic proximity Read ↗

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.Semantic proximity Read ↗

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.